Abstract:In 2022, an estimated 39 million people worldwide were living with the human immunodeficiency virus type 1 (HIV-1). Among them, 29.8 million people (76%) were accessing antiretroviral therapy (ART) (Global HIV & AIDS statistics, Fact sheet, UNAIDS; https://www.unaids.org/en/resources/fact-sheet ). By targeting essential stages of HIV-1 replication cycle, ART suppresses viral replication, preserves immune function and prevents the development of acquired immunodeficiency syndrome (AIDS) [1] . People with HIV-1 (PWH) who adhere to ART typically experience improved health and a life expectancy that is only a few years shorter than that of uninfected individuals [2] . Nevertheless, despite the undeniable success of ART, it is not curative and has to be taken lifelong. The primary challenge in achieving a cure for HIV-1 lies in the establishment, in the early course of infection, and lifelong persistence of the viral reservoir, located in resting memory CD4+ T cells and other cell types, primarily in peripheral blood and lymphoid organs [3–5] . The HIV-1 reservoir decays so slowly over time [6,7] that its lifelong persistence is guaranteed in the absolute majority of cases. Such long-term persistence is due to integration of the viral genome into the host chromosome as part of HIV-1 replication cycle. Once integrated, the provirus persists for the lifetime of the cell, and division of an infected cell provides each progeny cell with a copy of the integrated provirus. The reservoir persists primarily through cellular longevity and proliferation [8–12] , although replenishment by low-level residual virus replication, for example due to limited penetration of antiretroviral drugs into tissues, has been suggested to contribute as well [13–15] .

Persistent HIV-1 transcription during ART: time to reassess its significance?